Cytotrait

CytotraitCytotrait
C

Cytotrait

Biotech startup using organelle engineering to develop novel, high-value traits for agricultural crops.

Website
2026Active5
Rate
Advertise here

About

Cytotrait is a biotechnology spinout from the University of Manchester that utilizes its proprietary Mutant Organelle Selection System (MOSS) to precisely edit chloroplast and mitochondrial genomes in plants. This technology enables the development of crops with enhanced yield, resilience, and new food traits, while potentially streamlining regulatory pathways compared to conventional nuclear genome engineering.

Technology stack

detected 2026-06-27
EmailGoogle Workspace
Stack
Squarespace
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Cytotrait do?

Cytotrait is a biotechnology spinout from the University of Manchester that utilizes its proprietary Mutant Organelle Selection System (MOSS) to precisely edit chloroplast and mitochondrial genomes in plants. This technology enables the development of crops with enhanced yield, resilience, and new food traits, while potentially streamlining regulatory pathways compared to conventional nuclear genome engineering.

How much funding has Cytotrait raised?

Cytotrait has raised a total of $3M in funding. The most recent round on record is Seed.

Where is Cytotrait headquartered?

Cytotrait is headquartered in United Kingdom.

When was Cytotrait founded?

Cytotrait was founded in 2026.

What industry does Cytotrait operate in?

Cytotrait operates in Agriculture, Biotechnology, Gene Editing, Biotech, Agritech, Deep Tech.

How many employees does Cytotrait have?

Cytotrait has approximately 5 people on record.

What is Cytotrait's valuation?

StartupHub estimates Cytotrait's effective valuation at $12.0M (range $7.5M to $18.0M, 21% confidence), based on comparable companies in the sector.